Skip to main content
- Press releases

Asceneuron Joins CPAD Consortium

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

- Press releases

Asceneuron Expands Scientific Advisory Board

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

- Press releases

Abbas Hussain Appointed as Chair of Asceneuron

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

- Press releases

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth

- Press releases

Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

- Press releases

Asceneuron Awarded Grant from The Michael J. Fox Foundation

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

- Press releases

Asceneuron Publishes Preclinical Efficacy Data on ASN90

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

- Press releases

Asceneuron to Provide Update on O-GlcNAcase Pipeline

Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences

- Press releases

Asceneuron CEO Dirk Beher to speak at AAIC 2021

Asceneuron CEO Dirk Beher to speak at Alzheimer’s Association International Conference

- Press releases

Asceneuron Appoints Catherine Moukheibir to its Board of Directors

Asceneuron Appoints Prominent Healthcare Leader Catherine Moukheibir to its Board of Directors